2oow: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
Line 1: Line 1:
[[Image:2oow.jpg|left|200px]]
{{Seed}}
[[Image:2oow.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2oow|  PDB=2oow  |  SCENE=  }}  
{{STRUCTURE_2oow|  PDB=2oow  |  SCENE=  }}  


'''MIF Bound to a Fluorinated OXIM Derivative'''
===MIF Bound to a Fluorinated OXIM Derivative===




==Overview==
<!--  
Pharmacophores are chemical scaffolds upon which changes in chemical moieties (R-groups) at specific sites are made to identify a combination of R-groups that increases the therapeutic potency of a small molecule inhibitor while minimizing adverse effects. We developed a pharmacophore based on a carbonyloxime (OXIM) scaffold for macrophage migration inhibitory factor (MIF), a protein involved in the pathology of sepsis, to validate that inhibition of a catalytic site could produce therapeutic benefits. We studied the crystal structures of MIF.OXIM-based inhibitors and found two opposite orientations for binding to the active site that were dependent on the chemical structures of an R-group. One orientation was completely unexpected based on previous studies with hydroxyphenylpyruvate and (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1). We further confirmed that the unexpected binding mode targets MIF in cellular studies by showing that one compound, OXIM-11, abolished the counter-regulatory activity of MIF on anti-inflammatory glucocorticoid action. OXIM-11 treatment of mice, initiated 24 h after the onset of cecal ligation and puncture-induced sepsis, significantly improved survival when compared with vehicle-treated controls, confirming that inhibition of the MIF catalytic site could produce therapeutic effects. The crystal structures of the MIF inhibitor complexes provide insight for further structure-based drug design efforts.
The line below this paragraph, {{ABSTRACT_PUBMED_17526494}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 17526494 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_17526494}}


==Disease==
==Disease==
Line 31: Line 35:
[[Category: Alternative ligand-binding mode]]
[[Category: Alternative ligand-binding mode]]
[[Category: Isomerase]]
[[Category: Isomerase]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 11:21:26 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 18:19:01 2008''

Revision as of 15:19, 27 July 2008

File:2oow.png

Template:STRUCTURE 2oow

MIF Bound to a Fluorinated OXIM Derivative

Template:ABSTRACT PUBMED 17526494

Disease

Known disease associated with this structure: Persistent Mullerian duct syndrome, type I OMIM:[600957], Rheumatoid arthritis, systemic juvenile, susceptibility to OMIM:[153620]

About this Structure

2OOW is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor., Crichlow GV, Cheng KF, Dabideen D, Ochani M, Aljabari B, Pavlov VA, Miller EJ, Lolis E, Al-Abed Y, J Biol Chem. 2007 Aug 10;282(32):23089-95. Epub 2007 May 25. PMID:17526494

Page seeded by OCA on Sun Jul 27 18:19:01 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=2oow&oldid=660268"